Novo Nordisk wraps up another weight management deal

In a bid to retain its leadership position in the ever-expanding obesity sector, Novo Nordisk (NOV: N) has inked another research collaboration, adding to a string of M&A and licensing deals over the past couple of years.

Metaphore Biotechnologies, a Flagship-founded biotechnology company, today joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.

The collaboration is signed under the broader strategic partnership with the Danish diabetes and obesity giant and Flagship Pioneering to develop a portfolio of novel treatment approaches for cardiometabolic and rare diseases.